Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40520-021-01917-9 http://scihub22266oqcxt.onion/10.1007/s40520-021-01917-9 34164799!8221095!34164799     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34164799&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Aging+Clin+Exp+Res 2021 ; 33 (8): 2355-2359 Nephropedia Template TP {{tp|p=34164799|t=2021. Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease |pdf=|usr=}}{{34164799}} gab.com Text Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease JO: Aging Clin Exp Res http://www.kidney.de/pget.php?&tw=1&pmid=34164799 #FOAvip BACKGROUND: Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate. AIM: To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS. METHODS: IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded. RESULTS: Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died. CONCLUSIONS: Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS. Twit Text FOAVip Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease ????Aging Clin Exp Res http://www.kidney.de/pget.php?&tw=1&pmid=34164799 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34164799 #FOAvip English Wikipedia <ref>{{Cite pmid|34164799}}</ref> Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease #MMPMID34164799 Calafat M; Gonzalez-Munoza C; Fortuny M; Roig C; Calm A; Mombiela A; Canete F; Bertoletti F; Gonzalez-Gonzalez L; Teller-Martin M; Gordillo J; Manosa M; Garcia-Planella E; Domenech E Aging Clin Exp Res 2021[Aug]; 33 (8): 2355-2359 PMID34164799show ga BACKGROUND: Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate. AIM: To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS. METHODS: IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded. RESULTS: Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died. CONCLUSIONS: Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS. |*COVID-19[MESH] |*Inflammatory Bowel Diseases/drug therapy/epidemiology[MESH] |Aged[MESH] |Humans[MESH] |Immunosuppressive Agents/adverse effects[MESH] |Risk Factors[MESH]Impact of immunosuppressants on SARS-CoV-2 infection in elderly patien(epmc).pdf DeepDyve Pubget Overpricing